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Because the indication of allograft (allogeneic stem cell transplantation [alloSCT]) for multiple myeloma (MM)
has widened in recent years, thanks to the development of reduced-intensity conditionings (RIC), it is still
unclear if myeloablative conditioning (MAC) remains appropriate. This study compares retrospectively out-
comes of patients undergoing either RIC or MAC regimens for MM. Based on the SFGM-TC registry, we
included 446 MM patients receiving alloSCT between 1999 and 2009 for whom a minimal data set was
available. Median follow-up for the entire cohort was 33.6 months (range, 0 to 164.5). RIC and MAC pop-
ulations were different regarding age (53.5 versus 47.1 years, respectively), number of prior autologous (auto)
SCTs (93.2% versus 79.6% had at least 2 autoSCTs), and stem cell source (90.2% versus 61.2% received pe-
ripheral blood). For RIC and MAC populations the nonrelapse mortality at 2 years was 24.6% and 22.4%,
respectively, progression-free survival 35.5% and 51.1%, and overall survival 59.5% and 66.7% (not signiﬁcant).
These outcomes were not affected by conditioning intensity either on univariate or multivariate analysis.
Despite some limitations in the study design, these results indicate that MAC should remain a valuable optionedgments on page 1458.
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Y. Beaussant et al. / Biol Blood Marrow Transplant 21 (2015) 1452e1459 1453in alloSCT for MM, especially for young and less-treated patient with no comorbidity. The constant progress in
induction treatments of MM and supportive care after alloSCT could improve these results in the near future.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION Transplant Procedures
Relapse or progression rates remain high in multiple
myeloma (MM), even though 3-year overall survival (OS)
rates currently approach 80%. However, long-term data
indicate a continuous risk of disease recurrence after front-
line treatment including autologous hematopoietic stem cell
transplantation (autoSCT) [1-6]. Allogeneic (allo)SCT can
provide long-term, stable remissions and is a therapeutic
option for patients presenting with MM relapse after
autoSCT, primary refractory disease, or adverse cytogenetic
features [7]. The beneﬁts associatedwith alloSCTare partially
linked to the graft-versus-myeloma effect, illustrated by
observations of sustained remissions observed after donor
lymphocyte infusions [8-10]. Additional beneﬁts may be
attributed to the infusion of a tumor-free graft combined to
the antitumor effect of the preparative regimen before
transplantation. Nevertheless, alloSCT in MM is still contro-
versial because of highmorbidity andmortality rates [11-14].
With lower nonrelapse mortality (NRM), the develop-
ment of a reduced-intensity conditioning (RIC) allograft in
the 1990s expanded the use of alloSCT in MM, allowing a
wider population to be allografted [15]. However, studies
that compared RIC versus autoSCT as ﬁrst-line treatment,
particularly in the tandem autoSCT/alloSCT setting, have
yielded conﬂicting results [16-21]. Thus, myeloablative con-
ditioning (MAC) alloSCT is traditionally reserved for young
patients with adverse prognostic factors and good perfor-
mance status and for patients with a disease refractory to
conventional and novel agents therapies [11,13,14]. Although
theMAC alloSCToutcome has appeared to improve over time
[22], it has become less frequently used, and very few studies
have directly compared RIC and MAC alloSCT for patients
with MM [23]. The present study describes the clinical
outcome of a French cohort of MM patients who underwent
alloSCT over a 10-year period with a focus on the use of a
MAC or RIC regimen.METHODS
Inclusion/Exclusion Criteria
All patients having undergone an alloSCT for MM in 31 French centers
from 1999 to 2009 as reported in the Société Française de Greffe deMoëlle et
de Thérapie Cellulaire registry were reviewed for eligibility. Patient data
were screened using the French ProMISe (European Group for Blood and
Marrow Transplantation [EBMT]) database. We included all patients un-
dergoing a ﬁrst alloSCT for whom a minimal data set was available based on
the Med-A record of the EBMT: diagnosis and pretransplantation treatment
characteristics, disease status at transplantation, donor type, conditioning
regimen, HLA matching, number of prior transplantations, grade of graft-
versus-host disease (GVHD), disease status after transplantation, and dis-
ease status at last follow-up. We directly retrieved missing data in each
center whenever possible, and the entire database was rechecked and
ﬁnalized in October 2013. Mismatched, ex vivo T celledepleted, and cord
blood allografts were excluded.
All patients gave their written informed consent according to French
national standards and regulations. Because of changes in medical practice,
a small number of recruited patients in the early years of RIC alloSCT (be-
tween 1995 and 1998), and the emergence of major new drugs in the
management of MM, we only selected patients grafted since 1999. Cytoge-
netic data were retrieved from the Intergroupe Francophone du Myélome
and the Myélome Autogreffe Groupe ﬁles.We assigned the type of conditioning regimen (RIC versusMAC) for each
patient according to the registry’s data as recorded in available patient ﬁles.
Investigators were contacted to conﬁrm the regimen actually received, and
we further cross-checked information according to the following rules. We
considered as myeloablative all regimens containing >8 mg/kg oral
busulfan, >600 cGy total body irradiation (TBI), 200 mg/kg cyclophos-
phamide, and multiple chemotherapy combinations containing high-dose
carmustine, etoposide, cytarabine, and melphalan. All other chemotherapy
combinations, with or without 600 cGy TBI and regardless of the dose of
melphalan, were deﬁned as RIC regimens, generally including ﬂudarabine.
A tandem allograft was deﬁned according to the registry’s data reported
by the local investigator or as a RIC alloSCT performed less than 6 months
after an autoSCT in patients with at least a partial response at the time of RIC
allograft. T cell depletion was deﬁned as the use of in vivo T celledepleting
antibodies, antithymocyte globulin, or antilymphocyte globulin. All centers
referred to the 1994 Consensus Conference on Acute GVHD Grading [24] for
grading acute GVHD (aGVHD) and to the 2005 National Institutes of Health
criteria [25] for grading chronic GVHD (cGVHD).Statistics
Response to treatment, relapse, and progressionwere deﬁned according
to the EBMT [26] and the International Myeloma Working Group [27]
criteria. Brieﬂy, complete remission (CR) was deﬁned as the absence of a
detectable monoclonal component in serum and urine and <5% bone
marrow plasma cells; of note, bone marrow evaluation was not systemati-
cally performed in all centers. Very good partial response was deﬁned as a
90% decrease in the blood monoclonal component level and a urine
monoclonal component lower than 100 mg in a 24-hour urine collection.
Partial response was deﬁned as a 50% decrease in the serum monoclonal
component or a 90% decrease in the urine monoclonal component. Relapse
from CR was deﬁned by the reappearance of serum or urine M-protein by
immunoﬁxation or electrophoresis and its >25% increase during the ﬁrst 6
months or with any clinical sign of progression such as CRAB (C ¼ calcium
[elevated], R ¼ renal failure, A ¼ anemia, B ¼ bone lesions) features [26,27].
Survival analyses were made using the Kaplan-Meier method, and log
rank tests were used to compare survival curves. Progression-free survival
(PFS) and OS were measured in months and calculated from the date of
alloSCT until the respective events. NRM was deﬁned as death due to any
cause, which occurred without previous progression or relapse after
transplantation. Chi-square and t-tests were used for comparisons, and a 2-
sided P < .05 was considered as signiﬁcant.
For aGVHD and cGVHD, we used the Cox proportional hazards model.
Bonferroni correction was used if several tests were performed on the same
sample. Multivariate analyses were made using the Cox proportional haz-
ards model. We calculated a propensity score for conditioning regimen type
(RIC or MAC) selection based on the following covariates: patient age,
number of prior treatments, time to transplantation, and disease status at
transplantation. Post-transplant outcomes were included in the model as
time-dependent covariates.RESULTS
Patients and Transplant Procedures
Between 1999 and 2009 the required data set was avail-
able for 446 patients treated in 31 French centers. Of this
group, 397were transplantedwith RIC and only 49withMAC
regimens. Only 31 patients (7.8%) received an alloSCT
without a previous autoSCT. Two hundred three patients
(45%) received an alloSCT in an advance disease stage after
>2 autoSCTs. The year of transplantation as a continuous
variable or 2005 versus >2005 did not inﬂuence outcome.
The RIC and MAC populations were statistically different
regarding age, number of prior autoSCTs, and stem cell
source (Table 1). The median follow-up for the entire cohort
was 33.6 months (range, 0 to 164.5): 31.7 and 51.4 months for
RIC and MAC, respectively (P ¼ .0467).
Table 1
Patients Characteristics
Variable RIC (n ¼ 397) MAC (n ¼ 49) P
Median age, yr (range) 54.6 (27.4-69.6) 47.1 (25.7-63.0) <.0001
Sex, male 243 (61.2) 36 (73.5) ns
Type of myeloma
IgG 210 27 ns
IgA 78 5
Light chain 83 12
Lambda 43 6
Kappa 39 6
Other 26 (6.5) 5 (9.62)
IgD 15 5
IgM 2 0
Nonsecretory 9 0
Unknown 1 0
No. of prior treatments
1 154 (38.8) 16 (32.7) ns
2 243 (61.2) 33 (67.3)
Cytogenetics
Unfavorable factor 79 (19.9) 12 (24.5) ns
Normal 40 (10.1) 8 (16.3)
Unknown 278 (70.0) 29 (59.2)
Bortezomib before transplantation
Yes 108 (27.2) 14 (28.6) ns
No 289 (72.8) 35 (71.4)
Prior autologous transplantation
None 24 (6.0) 10 (20.4) .0018
1 373 (93.2) 39 (79.6)
Tandem* 163 (41.1) 18 (36.7)
Remission status at transplantation
CR 62 (15.6) 11 (22.4) ns
Partial response 276 (69.5) 32 (65.3)
Relapse/progression 32 (8.1) 4 (8.2)
Stable disease 27 (6.8) 2 (4.1)
ns indicates nonsigniﬁcant.
Values are number of patients with percents in parentheses, unless other-
wise indicated.
* Planned tandem transplantation or allograft less than 6 months after
autograft without documented relapse.
Table 2
Transplant Characteristics
RIC (n ¼ 397) MAC (n ¼ 49) P
Time to transplantation
<12 months 102 (25.7) 19 (38.8) ns
Cell source
Bone marrow 39 (9.8) 19 (38.8) <.0001
Peripheral blood stem cells 358 (90.2) 30 (61.2)
Donor
Identical sibling 298 (75.1) 33 (67.3) ns
Matched unrelated 99 (24.9) 16 (32.7)
Donor age 46.8 43.3 ns
CMV donor/recipient
/þ 87 (21.9) 11 (22.4) ns
/ 108 (27.2) 19 (38.8)
Conditioning regimen
CyclophosphamideeTBI
(12 Gy)
22
Busulfanecyclophosphamide 9
Cyclophosphamidee
ﬂudarabine
6
MelphalaneTBI (12 Gy) 4
Busulfan (>8 mg/kg)e
ﬂudarabine
2
Cyclophosphamidee
thiotepaeTBI (12 Gy)
2
Cytarabineebusulfane
ﬂudarabine
1
Cyclophosphamide 1
Cyclophosphamidee
melphalaneTBI (12 Gy)
1
TBI þ melphalan þ
ﬂudarabine
1
Busulfan (<8 mg/kg)e
ﬂudarabine
199
FludarabineeTBI (2 Gy) 114
Fludarabineemelphalan 32
TBI (2 Gy) 22
Fludarabineemelphalane
TBI (2 Gy)
13
Fludarabineetreosulfan 8
CyclophosphamideeTBI
(<ou ¼ 6 Gy)
2
Fludarabine 1
BusulfaneﬂudarabineeTBI 1
Cyclophosphamide
(<200 mg/kg)e
ﬂudarabine
1
MelphalaneTBI (2 Gy) 1
TBI þ cyclophosphamide þ
melphalan þ busulfan
1
Busulfan þ melphalan þ
ﬂudarabine
2
GVHD prophylaxis
CSA 158 (39.8) 5 (10.2) <.0001
CSA-MMF 155 (39.1) 11 (22.4)
CSA-MTX 54 (13.6) 32 (65.3)
Other 14 (3.7) 0 (0.0)
Unknown 16 (4.0) 1 (2.0)
T cell depletion
ATG or ALG 162 (40.8) 13 (26.5) ns
No 235 (59.2) 36 (73.5)
CMV indicates cytomegalovirus; CSA, cyclosporine A; MMF, mycophenolate
mofetil; MTX, methotrexate; ATG, antithymocyte globulin; ALG, anti-
lymphocyte globulin.
Values are number of patients with percents in parentheses, unless other-
wise indicated.
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genetic factors, but complete cytogenetic data were available
for only 29.0% of RIC and 38.7% of MAC patients. In RIC and
MAC groups, respectively, 64.6% and 50% of patients with an
unfavorable cytogenetic factor presented a deletion of
chromosome 13 alone, 5.1% and 25.0% a deletion of chro-
mosome 17 alone, 0% and 8.3% translocations involving
chromosome 14, 29.1% and 16.7% a deletion of chromosome
13 associated with a deletion of chromosome 17 and/or
translocations involving chromosome 14, and 1.3% and 0%
deletion of chromosomes 17 and translocations involving
chromosome 14.
For MAC, TBI (6  200 cGy) was used in 30 cases (61.2%),
in association with alkylating agents; busulfan was associ-
ated with cyclophosphamide in 9 cases (18.4%). For RIC,
regimens were based on ﬂudarabine in 371 cases (93.5%) and
associated with a single dose of 200 cGy TBI in 128 cases
(32.2%), with busulfan in 203 cases (51.1%), and with
melphalan in 47 cases (11.8%). GVHD prophylaxis was based
on cyclosporine alone or in combination with methotrexate
or mycophenolate mofetil. Antithymocyte globulin or anti-
lymphocyte globulin was administered in 162 RIC patients
(40.8%) and 13 MAC patients (26.5%) (P ¼ ns, Table 2).
Engraftment and GVHD
Graft failure was documented in 4 RIC patients (1.0%; 1
with no engraftment and 3 with graft rejection) and 1 MAC
patient (no engraftment). Mean time for neutrophil recovery
(neutrophils [PNN]> .5 g/L) was 16.0 9.2 days in the wholecohort (n ¼ 380), 15.8  9.6 in the RIC cohort (n ¼ 334), and
17.7  5.3 in the MAC cohort (n ¼ 46) (P ¼ .05). Time for
neutrophil recovery was signiﬁcantly shorter for patients
receiving peripheral blood stem cells than for those receiving
bone marrow (15.5 and 18.9 days, respectively; P ¼ .0007),
independently of the intensity of the conditioning regimen
used. Platelet and erythroid reconstitutionwere not analyzed
because of insufﬁcient data.
Figure 1. OS, PFS, and NRM in 448 allografts for myeloma patients with
reduced-intensity (RIC, continuous line) or myeloablative conditioning (MAC,
dotted line) regimens.
Table 3
Causes of Death
Cause RIC MAC P
Relapse or progression of original disease 145 (55.6) 15 (55.6) ns
SCT related 100 (38.3) 9 (33.3)
GVHD 29 (29) 4 (44.4)
Infection 23 (23) 2 (2.2)
GVHD þ infection 18 (18) 1 (1.1)
Other 13 (13) 1 (1.1)
Not clear 17 (17) 1 (1.1)
Secondary malignancy 7 (2.7) 0 (0)
Other 6 (2.3) 1 (3.7)
Unknown 3 (1.1) 2 (7.4)
Total 261 27
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aGVHD (n ¼ 63 and n ¼ 162 for grades I and II to IV,
respectively), and 132 patients (29.6%) were dead before the
event, giving a relative rate of 58.7%. Type of conditioning
(RIC versus MAC), type of GVHD prophylaxis, in vivo T cell
depletion, and nature of stem cell source and donor sex did
not affect signiﬁcantly grades II to IV aGVHD rate in univar-
iate analysis. Occurrence of grades II to IV aGVHD (36.4%) was
signiﬁcantly reduced in identical siblings when compared
with matched unrelated transplants (31.8% and 45.6%,
respectively; P ¼ .0007). Severe (grades III to IV) aGVHD was
observed in 72 patients and was equally distributed between
the 2 groups, with 64 cases for RIC (16.1%) and 8 cases for
MAC (16.3%).
cGVHD was documented in 221 patients (49.6%), and 116
(26.0%) were dead before the event, giving a relative rate of52.5%, 195 in RIC and 26 in MAC (hazard ratio [HR], .883; P ¼
ns). Limited cGVHD was observed in 103 cases (23.1%) and
extensive cGVHD in 107 cases (24.0%), with no signiﬁcant
difference between RIC and MAC groups. cGVHD rate was
signiﬁcantly higher in alloSCT using peripheral blood stem
cells compared with bone marrow (HR, 2.071; P ¼ .0079).
cGVHD rates were also elevated in male patients receiving
grafts from female donors compared with other sex match-
ing (HR, 1.730; P ¼ .0002), and all other comparisons were
nonsigniﬁcant. Type of donor, type of GVHD prophylaxis, and
in vivo T cell depletion did not affect signiﬁcantly the
occurrence of cGVHD.Tumor Response and Survival
In the RIC and MAC groups, respectively, 168 (42.3%) and
27 (55.1%) patients achieved CR (P ¼ ns) within 3 months
after transplantation, whereas only 62 (15.6%) and 11 (22.4%)
were in CR before conditioning and 142 (35.8%) versus 11
(22.4%) patients achieved partial remission (P ¼ ns) after
alloSCT. There were equivalent rates of stable disease and
progression in the RIC and MAC groups, 86 (21.7%) versus 11
(22.4%), respectively (P ¼ ns). The relapse rate of patients in
CR after alloSCT was 47.0% in the RIC group and 37.0% in the
MAC group (P ¼ ns); mean time for relapse was 19.8 versus
29.0 months, respectively (P ¼ ns). We did not have any in-
formation on sites of relapse after the allogeneic procedure,
especially on extramedullary relapses. We identiﬁed 52 pa-
tients receiving lenalidomide and 87 patients receiving
bortezomib in case of relapse after alloSCT with a global
response rate of 80%. One early death occurred after RIC, due
to grade IV aGVHD, and none after MAC regimens. At the
time of last follow-up, 155 patients (34.8%) were still alive
(33.8% and 42.9% of the RIC and MAC patients, respectively),
with 120 in continuous CR (26.4% of the RIC patients and
30.6% of the MAC patients, P ¼ ns).
At 2 and 5 years, respectively, OS rates were 59.5% and
37.9% for RIC patients versus 66.7% and 53.1% for MAC pa-
tients, PFS rates were 35.5% and 19.5% for RIC patients versus
51.1% and 26.7% for MAC patients, and NRM rates were 24.6%
and 33.3% for RIC patients versus 22.4% and 44.7% for MAC
patients. The differences between MAC and RIC regimens
were not signiﬁcant (Figure 1). Causes of the 288 deathswere
not signiﬁcantly different between the 2 groups (Table 3).
The major cause of death was MM in 55% cases. No other
predominant cause of death was reported in the RIC or MAC
groups; veno-occlusive disease was not reported as a major
cause of death in the MAC group.
Univariate analyses of survival outcomes are presented in
Table 4. Multivariate analyses of survival outcomes included
Table 4
Univariate Analysis of Factors Inﬂuencing Outcome (Entire Cohort)
Variable n P
OS PFS NRM
Sex (M vs. F) 443 ns ns ns
Age (<vs.  median age) 443 .0061 .0285 .0108
Transplantation date (<vs 2006) 443 ns ns ns
Type of myeloma 443 ns .0121 ns
Cytogenetic abnormality (1 vs. 0) 138 ns ns ns
b2-microglobulin (<3 vs. 3) 87 ns ns ns
Number of treatment lines
before alloSCT (<2 vs. 2)
443 ns ns ns
Bortezomib use before alloSCT 443 ns ns .0062
Tandem procedure 443 ns ns ns
Time to alloSCT after diagnosis
(12 vs. >12 mo)
443 .0033 .0108 ns
Disease status at transplantation
(CR vs. other)
418 ns ns ns
Donor type (phenotype vs.
genotype identical)
410 ns ns .0087
Type of conditioning 443 ns ns ns
Stem cell source (bone marrow
vs. peripheral blood)
443 ns ns ns
T cell depletion 443 ns ns ns
aGVHD (grade  I vs. >I) 442 <.0001 .0267 <.0001
cGVHD
None vs. limited vs. extensive 382 ns <.0001 ns
None vs. limited or extensive 382 ns .0001 ns
Y. Beaussant et al. / Biol Blood Marrow Transplant 21 (2015) 1452e14591456the following factors: propensity score, prior autoSCT, con-
ditioning type, bortezomib use before alloSCT, tandem pro-
cedure, donor type, aGVHD, and cGVHD. In multivariate
analysis, only grades 0 to I acute GVHD as compared with
aGVHD  grade II was associated with a better OS and a
lower NRM, and the beneﬁcial role of cGVHD on PFS was not
conﬁrmed in the multivariate model independently of its
extension (Table 5).DISCUSSION
The present study reﬂects the French experience of
alloSCT for MM in the last decade and offers a retrospective
comparison of outcomes after either RIC or MAC regimens in
a large population. To recruit a signiﬁcant number of pa-
tients, we needed to study over a 10-year period in more
than 30 centers because the use of alloSCT in MM patients is
rare. Physicians in charge of MMpatients generally prefer the
use of emerging new molecules and in young patients mul-
tiple autoSCT. AlloSCT was proposed as a frontline treatment
in only 6% of patients in the RIC group and 20% in the MAC
group, numbers too small to perform a subgroup analysis.
More than 70% of alloSCTs were realized after at least 2
autoSCTs in patients with advanced disease stages. The most
current and common practices are highlighted, as only
alloSCTs performed between 1999 and 2009 were selected
and more debatable procedures such as mismatched, ex vivo
T celledepleted, and cord blood allografts were excluded.
The year of transplantation did not signiﬁcantly affect
outcome, conﬁrming the homogeneity of patients’ care along
the study period. The deﬁnition of regimen intensity is stillTable 5
Factors Associated with OS, PFS, and NRM in Multivariate Analysis
OS (n ¼ 335) P PFS (n ¼ 329
RR (95% CI) RR (95% CI)
aGVHD 0 or I vs. II .577 (.433-.769) .00002 .817 (.629-1
No cGVHD .98 (.738-1.302) ns 1.157 (.886-1
RR indicates relative risk; CI, conﬁdence interval.controversial, and we chose to include high doses of cyclo-
phosphamide in the MAC group when the dose was 200
mg/kg, which is higher than the usual dose of 120 mg/kg. In
association with ﬂudarabine, this regimen is not really
myeloablative but could provide a high toxicity rate, which is
why we decided to include these patients in the MAC group.
As expected, a wider proportion of the cohort received a
RIC regimen, reﬂecting the shift in clinical practice that
occurred in alloSCT strategy in the late 1990s following the
emergence of so-called reduced/nonmyeloablative condi-
tioning [15,28]. This shift is mainly supported by prospective
studies that reported high NRM in MAC-treated groups,
ranging from 40% to 60% [2,12,13,29]. With the assumption
that RIC regimens would be associated with less NRM,
several prospective studies assessed these conditionings
within a tandem procedure and reported 5-year OS rates
ranging from35% to 61%, with NRM rates ranging from10% to
16% in newly diagnosed MM [16,18,20,21]. Björkstrand et al.
[16] and Giaccone et al. [17] reported a superior long-term
outcome with tandem auto/RIC alloSCT compared with
autoSCT for de novo MM. Conversely, 3 other major studies
found no superiority with RIC alloSCT [18-20]. Only retro-
spective studies assessed the prognostic inﬂuence of
different conditioningmodalities in MMpatients undergoing
alloSCT, most of them showing signiﬁcant improvements of
NRM in association with the introduction of RIC alloSCT, and
some of them showing differences in PFS and/or OS (Table 6)
[28,30,31,34,35].
In the present study, direct comparison of MAC and RIC
groups found no signiﬁcant difference in terms of OS, PFS,
and NRM. The fact that RIC patients were generally older and
more heavily treated than MAC patients at time of the allo-
graft could explain the higher NRM rate (33.3% at 5 years) in
this group as compared with MAC patients who were
younger and probably highly selected. In addition, as
assumed by Bensinger et al. [30], NRM associated with MAC
alloSCT may have decreased over time because of improve-
ments in supportive care and GVHD/infection prophylaxis
and treatments. The supportive care after allogeneic
transplantation (antifungal therapy, deﬁbrotide for veno-
occlusive disease, management of GVHD) are in constant
progression and will probably contribute to reduce NRM and
enhance survival in the next few years [34,35]. Within the
RIC and MAC groups, respectively, various conditioning
regimens were used, probably reﬂecting the effort to ﬁt dose
intensity to each patient’s general condition and comorbid-
ities. The intensity of regimens in the RIC group was more
intense than in other reports, which could probably explain
the fact that NRM at 1 year was close to 20%, similar to MAC
regimens for other indications [35].
aGVHD and cGVHD were not statistically different
between RIC and MAC groups but signiﬁcantly affected
survivals with a beneﬁcial effect of GVHD on PFS that
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on the cell source (bone marrow versus peripheral blood
stem cells). As shown in the retrospective study reported by
El-Cheikh et al. [32], PFS curves of the RIC group seem to
stabilize in time after 6 years post-alloSCT in a plateau.
However, late relapses after RIC alloSCT may occur as shown
by Sahebi et al. [33] and in the present study with a few
relapses observed until 90 months post-alloSCT.
High-risk factors, including relapse/refractory disease
after autoSCT and/or unfavorable cytogenetic factors, did
not affect survival in our study. However, the lack of cyto-
genetic data and small sample of refractory patients in our
cohort preclude rigorous statistical evaluation of outcomes
associated with such factors. However, studies indicate RIC
alloSCT could be of interest in these presumably high-risk
subgroups [36,37]. The induction regimens for MM have
dramatically changed over the last years, and the combi-
nation of new immunomodulators such as proteasome in-
hibitors and IMiDs could offer to MM patients very high
rates of response, including a large proportion of CRs
[38,39]. The integration of these novel therapies with the
immunotherapeutic platform of allotransplant offers
considerable promises in the treatment of MM in the near
future but still needs to be evaluated [39,40]. In our study,
bortezomib treatment before alloSCT worsened NRM in a
univariate analysis but did not affect survival outcomes in a
multivariate analysis; the use of other new agents, such as
IMiDs, were not evaluated in this study because of the small
representation in the data available. The use of these agents
before alloSCT could select refractory patients with a more
aggressive disease than that traditionally observed
after standard chemotherapy. Coman et al. [41] already
describedmodalities of relapse treatments with bortezomib
and lenalidomide after alloSCT in this same French cohort
(unpublished data, Coman T, personal communication) with
a signiﬁcant response rate and sometimes with lenalido-
mide the occurrence of GVHD. We do not have any infor-
mation on extramedullary relapses, which seems to be quite
frequent in this setting. The place of these new agents
within the allograft strategy is still undeﬁned, but their
immunomodulatory actions are likely to remain effective
also in cases of disease relapse after alloSCT [4,5,41-44].
The limitations of this work include principally the
retrospective nature of the study and the small size of the
MAC group, which precludes deﬁnitive conclusions with
regard to clinical outcome comparison. The small number of
MM patients undergoing alloSCT is also a strong limitation to
analyze a large series on a short time period, especially as
patients were further divided among many disease stages,
conditioning regimens, and other various characteristics.
Hence, comparisons should be done with cautions. Never-
theless, this study highlights the predominant indication of
RIC in MM patients undergoing alloSCT and may offer an
interesting contribution in the choice of conditioning
regimen. Certainly RIC conditioning offers the possibility to
allograft a wider population, as MM mostly affects elderly
patients and alloSCT is proposed only after at least 2 or 3
pervious treatment lines. However, it could be beneﬁcial to
consider more myeloablative regimens in younger and high-
risk patients, as NRM was comparable in both groups. This
emphasizes that, more than risk factors for the disease
course, age and comorbidity are determinant factors for
choosing the intensity of conditioning.
Because no conclusive differences in outcome after the
intensity of conditioning are clearly shown, in the era of
Y. Beaussant et al. / Biol Blood Marrow Transplant 21 (2015) 1452e14591458novel antimyeloma agents, the role of alloSCT inMMmust be
redeﬁned. The progress in supportive care and the constant
reduction of NRM after allogeneic transplantation should
also be taken into account to include allogeneic therapy in
the future management of MM. The use of alloSCT databases
in retrospective well-designed trials offers the opportunity
to deﬁne the best timing and candidates for alloSCT in MM,
especially as the emergence of targeted molecules and
monoclonal antibodies makes it unlikely that a large pro-
spective randomized trial on alloSCT in MM will be con-
ducted in the near future to answer these questions.ACKNOWLEDGMENTS
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